India, Aug. 4 -- Rhythm Pharmaceuticals, Inc. (RYTM) on Tuesday reported a wider second-quarter net loss as higher operating expenses more than offset strong revenue growth, driven by increased global sales of IMCIVREE. The company also provided clinical updates and lowered its full-year 2026 operating expense guidance.
Company Profile
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare MC4R pathway diseases. Its portfolio includes the approved obesity drug IMCIVREE (setmelanotide) and pipeline candidates bivamelagon and RM-718.
FY26 Second Quarter Results
For the second quarter ended June 30, 2026, the company reported a year-over-year loss attrib...